Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Integrated Genomic-Transcriptomic Study Highlights Accumulation of Genetic Variants and Activation of Inflammatory Pathways

Malathi Kandarpa, PhD, Kristen Pettit, MD, Tingting Qin, PhD, Yi-Mi Wu, PhD, Dan Robinson, PhD, Maureen Sartor, PhD, Arul Chinnaiyan, MD, Moshe Talpaz, MD

Blood (2019) 134 (Supplement_1): 4212.

https://doi.org/10.1182/blood-2019-128301

Published: 2019

Journal Articles

Phase 1b Study of the Epichaperome Inhibitor PU-H71 Administered Orally with Ruxolitinib Continuation for the Treatment of Patients with Myelofibrosis

Naveen Pemmaraju, MD, Krishna Gundabolu, MBBS, Kristen Pettit, MD, Moshe Talpaz, MD, Nikolai A. Podoltsev, MD PhD, Gary J. Schiller, MD, Peter Eisenberg, MD, Hagop Youssoufian, MD, Susan Duggan, RN, MBA, Barbara Wallner, PhD, Srdan Verstovsek, MD PhD

Blood (2019) 134 (Supplement_1): 4178.

https://doi.org/10.1182/blood-2019-130310

Published: 2019

Journal Articles

A Phase 2a Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Myelofibrosis

Kristen Pettit, MD, Aaron T. Gerds, MD MS, Abdulraheem Yacoub, MD, Justin M. Watts, MD, Maciej Tartaczuch, MD, Terrence J Bradley, MD, Jake Shortt, MBBS FRACP FRCPA PhD, William S. Stevenson, MBBS,PhD, Natasha Joan Curtin, MDFRACP,FRCPA, James M. Rossetti, DO, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Georges Natsoulis, PhD, Amber Jones, MA, Moshe Talpaz, MD, Jennifer Peppe, BS, David M Ross, MD PhD, Hugh Young Rienhoff, Jr., MD

Blood (2019) 134 (Supplement_1): 556.

https://doi.org/10.1182/blood-2019-123244

Published: 2019

Journal Articles

Multi-Center Retrospective Evaluation of High-Dose Cytarabine Based Induction Versus CPX-351 Induction in Patients with Secondary AML

Lydia Benitez, PharmD, Anthony J. Perissinotti, PharmD, Caitlin R. Rausch, PharmD, Jeff Klaus, PharmD, Stephen Michael Clark, PharmD, Michael Filtz, PharmD, Kelley L Ratermann, PharmD, Carissa F. Treptow, PharmD, Shawn Griffin, PharmD, Marissa Olson, PharmD, Mallory Crain, PharmD, Kristen Pettit, MD, Patrick W. Burke, MD, Dale L. Bixby, MD, Bernard Lawrence Marini, PharmD

Blood (2019) 134 (Supplement_1): 2639.

https://doi.org/10.1182/blood-2019-122189

Published: 2019

Journal Articles

Integrative Next Generation Sequencing of Myeloproliferative Neoplasms and Correlation of Genetic Variations to Disease Severity

Malathi Kandarpa, PhD, Kristen Pettit, MD, Yi-Mi Wu, PhD, Qing Li, MD, Robert Lonigro, Dan Robinson, PhD, Luke F. Peterson, PhD, Philip S Boonstra, PhD, Arul Chinnaiyan, MD, Moshe Talpaz, MD

Blood (2018) 132 (Supplement 1): 4324.

https://doi.org/10.1182/blood-2018-99-113418

Published: 2018

Journal Articles

Final Results from a Phase I Trial Combining Selinexor with High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in Acute Myeloid Leukemia (AML)

Amy Wang, MD MPH, Howard Weiner, Richard A. Larson, MD, Olatoyosi Odenike, MD, Andrew S Artz, MD, Michael R. Bishop, MD, Lucy Godley, MD PhD, Michael Thirman, MD, Satyajit Kosuri, MD, Jane Churpek, MD, Emily K Curran, MD, Kristen Pettit, MD, Wendy Stock, MD, Hongtao Liu, MD PhD

Blood (2018) 132 (Supplement 1): 4073.

https://doi.org/10.1182/blood-2018-99-120244

Published: 2018

Journal Articles

Lenalidomide Plus Hypomethylating Agent for Acute Myeloid Leukemia (AML) with Recurrent Genetic Abnormalities -AML with Inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, Mecom

Lauren E. Merz, BA, Anthony J. Perissinotti, PharmD, Bernard Lawrence Marini, PharmD, Ashley Crouch, BS, Kristen Pettit, MD, Patrick W. Burke, MD, Harry P. Erba, MD PhD, Dale L. Bixby, MD PhD

Blood (2018) 132 (Supplement 1): 4042.

https://doi.org/10.1182/blood-2018-99-110854

Published: 2018

Journal Articles

Combination of Selinexor with High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in Acute Myeloid Leukemia (AML) Is Feasible and Tolerable

Amy Y Wang, MD, Howie Lawrence Weiner, Margaret Green, Richard A. Larson, MD, Olatoyosi Odenike, MD, Andrew Artz, MD, Lucy A Godley, MD, PhD, Michael J. Thirman, MD, Jane E Churpek, MD, Emily K. Curran, MD, Kristen Pettit, MD, Wendy Stock, MD, Hongtao Liu, MDPhD

Blood (2016) 128 (22): 212.

https://doi.org/10.1182/blood.V128.22.212.212

Published: 2016

NARROW

Integrated Genomic-Transcriptomic Study Highlights Accumulation of Genetic Variants and Activation of Inflammatory Pathways

Phase 1b Study of the Epichaperome Inhibitor PU-H71 Administered Orally with Ruxolitinib Continuation for the Treatment of Patients with Myelofibrosis

A Phase 2a Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Myelofibrosis

Multi-Center Retrospective Evaluation of High-Dose Cytarabine Based Induction Versus CPX-351 Induction in Patients with Secondary AML

Integrative Next Generation Sequencing of Myeloproliferative Neoplasms and Correlation of Genetic Variations to Disease Severity

Final Results from a Phase I Trial Combining Selinexor with High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in Acute Myeloid Leukemia (AML)

Lenalidomide Plus Hypomethylating Agent for Acute Myeloid Leukemia (AML) with Recurrent Genetic Abnormalities -AML with Inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, Mecom

Combination of Selinexor with High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in Acute Myeloid Leukemia (AML) Is Feasible and Tolerable

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only